Drug · CHEMBL710
FINASTERIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FINASTERIDE. Drugs and targets, record CHEMBL710. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL710
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 12 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SRD5A2 | 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Steroid 5-alpha-reductase 2 inhibitor | INHIBITOR | https://conductscience.org/library/genes/6716 |
Source ChEMBL
Diseases12
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 12Source Open Targets
See all 12 diseasesTrials65
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01231607 | Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia | Phase 3 | 917 | 2012-10-04 | finasteride | Its name | ClinicalTrials.gov |
| NCT01139762 | A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms | Phase 3 | 696 | 2013-02-27 | finasteride | Its name | ClinicalTrials.gov |
| NCT03004469 | Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia | Phase 3 | 458 | 2019-04-19 | finasteride | Its name | ClinicalTrials.gov |
| NCT01296672 | 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer | Phase 4 | 383 | 2017-09-08 | finasteride | Its name | ClinicalTrials.gov |
| NCT00438464 | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery | Phase 2 | 204 | 2016-03-09 | finasteride | Its name | ClinicalTrials.gov |
| NCT01342367 | Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer | 74 | 2021-10-28 | finasteride | Its name | ClinicalTrials.gov | |
| NCT00475501 | 5-Alpha Reductase and Anabolic Effects of Testosterone | Phase 2 | 60 | 2014-07-31 | finasteride | Its name | ClinicalTrials.gov |
| NCT00736645 | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | Phase 2 | 55 | 2017-11-28 | finasteride | Its name | ClinicalTrials.gov |
| NCT02213107 | Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | Phase 2 | 43 | 2024-11-13 | finasteride | Its name | ClinicalTrials.gov |
| NCT02248701 | Testosterone Plus Finasteride Treatment After Spinal Cord Injury | Phase 2 | 33 | 2023-09-29 | finasteride | Its name | ClinicalTrials.gov |
1 to 10 of 65
See all 65 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
5ARI Users vs Non 5ARI Users: Suicide (Based on Administrative Data Elements From Ontario Registrar General Death Database, National Ambulatory Care Reporting System, Hospital Discharge Abstracts, and Ontario Regional Mental Health Database) | 38 of 93,197 | 36 of 93,197 | 186,394 | NCT02876757 | Trial comparisons |
| 5ARI Users vs Non 5ARI Users: deaths from any cause | 160 of 93,197 | 139 of 93,197 | 186,394 | NCT02876757 | Trial comparisons |
| 5ARI Users vs Non 5ARI Users: Suicide Attempt (Based on Administrative Data Elements From National Ambulatory Care Reporting System, and Ontario Regional Mental Health Database) | 169 of 93,197 | 130 of 93,197 | 186,394 | NCT02876757 | Trial comparisons |
| 5ARI Users vs Non 5ARI Users: serious adverse events | 0 of 93,197 | 0 of 93,197 | 186,394 | NCT02876757 | Trial comparisons |
5ARI Users vs Non 5ARI Users: Depression (Based on Administrative Data Elements From Hospital Discharge Abstract Database, and Ontario Regional Mental Health Database and Ontario Health Insurance Plan) | 1,750 of 89,844 | 1,231 of 89,844 | 179,688 | NCT02876757 | Trial comparisons |
| Finasteride vs Placebo: deaths from any cause | 0 of 306 | 0 of 77 | 383 | NCT01296672 | Trial comparisons |
| Finasteride vs Placebo: serious adverse events | 3 of 306 | 1 of 77 | 383 | NCT01296672 | Trial comparisons |
| Arm I (Finasteride) vs Arm II (Placebo): serious adverse events | 0 of 89 | 0 of 94 | 183 | NCT00438464 | Trial comparisons |
| SOC Cohort vs Oral ADT Group: deaths from any cause | 8 of 30 | 7 of 40 | 70 | NCT01342367 | Trial comparisons |
| SOC Cohort vs Oral ADT Group: serious adverse events | 2 of 30 | 2 of 40 | 70 | NCT01342367 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials18
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Line Angle Matching | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL710
GET https://conductscience.org/api/drugs/v1/CHEMBL710/trials?page=2